Related Experiment Video

Updated: Nov 15, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

95.3K

Resveratrol Affects Insulin Signaling in Type 2 Diabetic Goto-Kakizaki Rats

Katarzyna Szkudelska1, Marzanna Deniziak2, Maciej Sassek1

  • 1Department of Animal Physiology, Biochemistry and Biostructure, Poznan University of Life Sciences, Wolynska 35, 60-637 Poznan, Poland.

International Journal of Molecular Sciences
|March 6, 2021
PubMed

Insights

Resveratrol treatment improved type 2 diabetes in Goto-Kakizaki rats by normalizing insulin receptor expression in skeletal muscle and glucose transporters in adipose tissue. This suggests a potential therapeutic role for resveratrol in managing diabetes.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Resveratrol, a diphenolic compound, exhibits beneficial effects, including anti-diabetic properties, though its mechanisms are not fully understood.
  • Type 2 diabetes is characterized by dysregulation of insulin signaling and glucose transport.
  • Goto-Kakizaki (GK) rats serve as a model for congenital type 2 diabetes.

Purpose of the Study:

  • To investigate the effects of resveratrol on insulin signaling pathways.
  • To evaluate resveratrol's impact on diabetes-associated dysregulation in GK rats.
  • To elucidate the molecular mechanisms underlying resveratrol's anti-diabetic actions.

Main Methods:

  • GK rats were administered resveratrol (20 mg/kg b.w.) for 10 weeks.
  • Insulin receptor expression and phosphorylation were analyzed in skeletal muscle and liver.
  • Insulin binding parameters (dissociation constant, binding capacity) were assessed.
  • Expression levels of glucose transporters (GLUT4, TUG) in adipose tissue and skeletal muscle were measured.
  • Blood levels of insulin, proinsulin, GIP, and GLP-1 were determined.

Main Results:

  • Resveratrol prevented decreased insulin receptor expression and phosphorylation in GK rat skeletal muscle.
  • Resveratrol normalized insulin binding parameters in skeletal muscle and liver.
  • Resveratrol treatment abolished decreased expression of GLUT4 and TUG in adipose tissue.
  • Resveratrol normalized TUG expression in skeletal muscle.
  • Resveratrol did not significantly alter blood levels of insulin, proinsulin, GIP, or GLP-1.

Conclusions:

  • Resveratrol partially ameliorates diabetes-associated dysregulation in GK rats.
  • Key findings include normalization of insulin receptor expression in skeletal muscle and glucose transporters (GLUT4, TUG) in adipose tissue.
  • Resveratrol demonstrates potential as a therapeutic agent for type 2 diabetes by improving insulin sensitivity and glucose uptake.
Keywords:
insulininsulin receptorresveratroltype 2 diabetes

More Related Videos

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats07:41

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

6.3K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.0K

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.9K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
437
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
570
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
345